Cyproheptadine (hydrochloride sesquihydrate)

[1]Feng YM, et al. Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase. BMC Cancer. 2015 Mar 17;15:134.|[2]Mao X, et al. Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood. 2008 Aug 1;112 (3) :760-9.|[3]Kacar S, et al. Cyproheptadine causes apoptosis and decreases inflammation by disrupting thiol/disulfide balance and enhancing the levels of SIRT1 in C6 glioblastoma cells. Toxicol In Vitro. 2021 Jun;73:105135. |[4]Hsieh HY, et al. Cyproheptadine exhibits antitumor activity in urothelial carcinoma cells by targeting GSK3β to suppress mTOR and β-catenin signaling pathways. Cancer Lett. 2016 Jan 1;370 (1) :56-65.|[5]He YL, et al. Cyproheptadine enhances the I (K) of mouse cortical neurons through sigma-1 receptor-mediated intracellular signal pathway. PLoS One. 2012;7 (7) :e41303.|[6]Shannar A, et al. Cyproheptadine inhibits in vitro and in vivo lung metastasis and drives metabolic rewiring. Mol Biol Rep. 2024 Nov 10;51 (1) :1139.|[7]Singh D, et al. Proconvulsant potential of cyproheptadine in experimental animal models. Fundam Clin Pharmacol. 2010 Aug;24 (4) :451-5.|[8]He YL, et al. Cyproheptadine Regulates Pyramidal Neuron Excitability in Mouse Medial Prefrontal Cortex. Neurosci Bull. 2018 Oct;34 (5) :759-768.|[9]Cakici I, et al. Hypoglycaemic effect of Momordica charantia extracts in normoglycaemic or cyproheptadine-induced hyperglycaemic mice. J Ethnopharmacol. 1994 Oct;44 (2) :117-21.